CLINICAL OUTCOMES IN PATIENTS &lt; 65 YEARS WITH NO OBSTRUCTIVE CORONARY DISEASE ON CORONARY ANGIOGRAM  by Sedlak, Tara et al.
Chronic CAD/Stable Ischemic Heart Disease
E1486
JACC March 27, 2012
Volume 59, Issue 13
CLINICAL OUTCOMES IN PATIENTS < 65 YEARS WITH NO OBSTRUCTIVE CORONARY DISEASE ON 
CORONARY ANGIOGRAM
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 11:00 a.m.-Noon
Session Title: Non-Obstructive CAD: What Are We Missing?
Abstract Category: 2. Chronic CAD/Stable Ischemic Heart Disease: Clinical
Presentation Number: 1200-135
Authors: Tara Sedlak, Mona Izadnegahdar, May Lee, Min Gao, Karin Humphries, C. Noel Bairey Merz, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Background: Major adverse cardiac events (MACE) in patients with no obstructive coronary artery disease (NO CAD) has been less well described 
as obstructive CAD particularly in the stable angina population. We evaluated clinical outcomes in patients < 65 years with stable angina following 
the diagnosis of NO CAD compared to obstructive CAD on coronary angiography (CA).
Methods: We studied all patients 20 - 65 years, with stable angina, undergoing CA in British Columbia (BC), Canada from July 1999 to March 
2002. NO CAD and obstructive CAD were defined as < 50% and > 50% luminal narrowing in any epicardial coronary artery, respectively. Freedom 
from MACE* was estimated using the Kaplan-Meier method and differences between groups were tested with a log-rank test.
Results: Of 4359 patients, 407 (9.3%) had NO CAD. At 1 year, freedom from MACE was 98.5% (95% CI 96.7, 99.3) in patients with NO CAD and 
95.8% (95% CI 95.1, 96.4) in patients with obstructive CAD. By 3 years, this difference reached only borderline significance: 93.2% (95% CI 88.9, 
95.9) for NO CAD vs 91.8% (95% CI 90.7, 92.8) for obstructive CAD (log rank p=0.046) (Figure 1).
Conclusions: In patients < 65 years with stable angina who underwent CA, MACE rates for NO CAD, while less than obstructive CAD, are 
not substantially different at 3 years. Given the elevated MACE rate in NO CAD patients, a prospective trial to examine the impact of anti-
atherothrombotic and anti-ischemic therapy on MACE in patients with NO CAD is warranted.
